Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amodiaquine + Potassium canrenoate with Exenatide or Glibenclamide in Acute Ischemic Stroke
2025-522796-28-00Phase 2Withdrawn
- Sponsor
- GENESIS Pharma
- Start
- Feb 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of amodiaquine, potassium canrenoate, exenatide and glibenclamide in ischemic stroke (3 arms), sponsored by GENESIS Pharma. Primary endpoint: Hemorrhagic transformation on imaging. Planned start Feb 2026; status: withdrawn.
02
Drugs
amodiaquinepotassium canrenoateexenatideglibenclamide
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on 2025-522796-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522796-28-00.